Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.

Related Articles

Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.

Psychiatr Genet. 2019 Jan 23;:

Authors: Balaj K, Nowinski L, Walsh B, Mullett J, Palumbo ML, Thibert RL, McDougle CJ, Keary CJ

Abstract
OBJECTIVES: Angelman syndrome (AS) is a neurogenetic disorder associated with impaired expression of the ubiquitin-protein ligase E3A gene on chromosome 15. AS results in intellectual disability with limited expressive language, epilepsy, ataxia, sleep impairment, and problematic behavior which may include anxiety. Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS.
METHODS: We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety.
RESULTS: We found significant improvement in symptoms of anxiety with buspirone. Patients tolerated long-term usage of the medication.
CONCLUSION: The findings of this study suggest that buspirone may be effective for the amelioration of behaviors related to anxiety in patients with AS, and well tolerated. Limitations include the open-label nature of these treatments, the small sample size and the absence of a control group.

PMID: 30681431 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2SgJJdr